WO1994016688A1 - Nutritive composition - Google Patents
Nutritive composition Download PDFInfo
- Publication number
- WO1994016688A1 WO1994016688A1 PCT/JP1994/000101 JP9400101W WO9416688A1 WO 1994016688 A1 WO1994016688 A1 WO 1994016688A1 JP 9400101 W JP9400101 W JP 9400101W WO 9416688 A1 WO9416688 A1 WO 9416688A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glutamine
- nutritional composition
- weight
- amino acid
- nutritional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Definitions
- the present invention relates to a nutritional composition such as an infusion solution, a nutrient, etc., containing -alanil-L-glutamine.
- a method for supplying nutrition to mammals including humans a method is known in which amino acid is supplied alone or mixed with a protein or vitamin or the like and injected or orally.
- amino acid is supplied alone or mixed with a protein or vitamin or the like and injected or orally.
- L-glutamine is required to be recruited because the decrease of L-glutamine in muscle is remarkable.
- L-glutamine cannot be contained in a nutritional composition prepared by heat sterilization due to poor heat stability in a solution state.
- L-glutamine which is unstable in a solution state
- a method of supplying L-glutamine as a dipeptide is used.
- L-aralanyl-L-glutamine is supplied.
- L-glutamin dipeptides such as L-aranil-L-glutamine, glycyl-L-glutamine, L-aspartyl-L-glutamine, L_glutamyl-L-glutamine, etc.
- L-glutamine glycyl-L-glutamine
- L-aspartyl-L-glutamine L_glutamyl-L-glutamine
- L_glutamyl-L-glutamine etc.
- a nutritional composition containing 5-alanyl-L-glutamine which has high solubility in water and good heat stability.
- Examples of the nutritional composition include an amino acid infusion or a nutritional supplement.
- the amino acid infusion according to the present invention includes isoleucine, leucine, lysine, and phenyl.
- Essential amino acids of L-forms such as alanine, methionine, threonine, tryptophan, pallin, arginine, histidine, alanine, aspartic acid, cystine, glutamic acid, proline, serine, tyrosine, and glycine, or essential amino acids thereof Containing one or more of the following salts and -aranyl-L-glutamine.
- the amino acid infusion may contain, if necessary, sugars such as glucose, fructose, xylitol, sorbitol, and maltose, polyhydric alcohols such as glycerin, soybean oil, cottonseed oil, sesame oil, egg yolk lecithin, soybean lecithin, and the like.
- sugars such as glucose, fructose, xylitol, sorbitol, and maltose
- polyhydric alcohols such as glycerin, soybean oil, cottonseed oil, sesame oil, egg yolk lecithin, soybean lecithin, and the like.
- Vita Mi emissions lipids, Vita Mi emissions A, Vita Mi emissions B ,, Vita Mi emissions B 2, Vita Mi emissions B 6, nicotinic acid, pan Toten acid, Vita Mi emissions (:, Vita Mi emissions D, Vita Mi emissions E, Piochin, Electrolytes such as vitamins such as folic acid, sodium chloride, sodium acetate, sodium chloride, magnesium sulfate, magnesium chloride, calcium chloride, sodium phosphate, sodium phosphate; iron, Includes halogens such as zinc, manganese, copper, iodine, cobalt and metals.
- ⁇ -Aranyl-L-glutamine used in the present invention is a known compound, and can be synthesized, for example, according to the method described in CA, Vol. 70, 38090n (1969).
- the amino acid infusion is composed of one or more amino acids constituting the above-mentioned amino acid infusion, the above-mentioned ingredients and / 3-aranyl-L-glutamine, and 3 / 3-aranyl-L-glutamine in a weight ratio of 3 3.
- the temperature should be raised to 25 to 50 ° C if necessary.
- the pH of the resulting solution is adjusted to 4.0 to 7.5 using acetic acid, hydrochloric acid, lactic acid, malic acid, citric acid, succinic acid, fumaric acid, sodium hydroxide, etc., and then heat sterilization and sterile filtration Perform sterilization procedures such as above to obtain an amino acid infusion.
- Amino acid infusion is usually used for intravenous administration.
- Table 1 shows one example of the composition of the amino acid infusion of the present invention.
- the nutritional supplement in the present invention is mainly used as an oral or enteral nutrition composition.
- oral administration it is preferable to use a mixture of water, proteins, carbohydrates, lipids, vitamins, minerals, flavors, sweeteners, flavors, pigments and the like.
- Proteins include casein, its hydrolyzate, gelatin, skim milk, egg yolk powder, etc.
- Carbohydrates include starch, dextrin, cyclodextrin, glucose, reduced maltose, lactose, malt extract, etc.
- lipids include medium-chain fatty acids and egg yolk oil
- vitamins include vitamin A, thiamine, and ribofura.
- Bottles pyridoxine, niacin, nontothenic acid, cyanocobalamin, L-ascorbic acid, sodium tocoprolol, etc., and minerals such as salt, potassium chloride, calcium chloride, iron lactate, etc. .
- Inosinic acid and the like are used as flavoring agents, aspartame, D-xylose, and D-sorbitol are used as sweeteners, citrate and orange flavors are used as flavoring agents, and 3-potency rotin and copper are used as pigments. Chlorophyll and the like.
- the nutritional supplement according to the present invention comprises water and at least 0.02 to 500 g (0.00 to 50% by weight) of protein, preferably 1 to 300 g (0.1 to 30% by weight), and carbohydrate.
- 0.0 to 800 g 0.02 to 80% by weight
- 1 to 500 g 0.1 to 50% by weight
- preferably 1 to 150 g (0.1 to 15% by weight) if necessary, 40 to 12
- the nutrient can be obtained in the form of a liquid or jelly, sealed in a moisture-proof bag, bottle, can or the like, and then sterilized by heating.
- the liquid after heat sterilization may be directly dried by freeze-drying or the like, and preserved. When used, the liquid may be dissolved in water or the like before use.
- L-Gnore evening Min 9% 0% According to Table 2, when heated for 20 minutes,; 3-aralanyl-L-glutamine was completely left, whereas the control L-aralanyl-L-glutamine was partially removed. About 90% of L-glutamine was degraded. Further, when heated for 120 minutes, L-glutamine was completely decomposed, whereas 99% of 3-alanyl-L-glutamine remained, and the residual ratio was higher than that of L-alanil_L-glutamine. Was.
- the nutritional composition containing / S-aralanyl-L-glutamine of the present invention is useful as an infusion solution, a nutritional supplement and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/295,842 US5432160A (en) | 1993-01-29 | 1994-01-26 | Nutrient composition |
| EP94905207A EP0634168A1 (en) | 1993-01-29 | 1994-01-26 | Nutritive composition |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5014240A JPH06227974A (ja) | 1993-01-29 | 1993-01-29 | 栄養組成物 |
| JP5/14240 | 1993-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1994016688A1 true WO1994016688A1 (en) | 1994-08-04 |
Family
ID=11855567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1994/000101 Ceased WO1994016688A1 (en) | 1993-01-29 | 1994-01-26 | Nutritive composition |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US5432160A (ja) |
| JP (1) | JPH06227974A (ja) |
| WO (1) | WO1994016688A1 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000032140A1 (en) * | 1998-11-30 | 2000-06-08 | Ivf Sciences Colorado, Inc. | System and sequential culture media for in vitro fertilization |
| US6649746B1 (en) | 1999-05-07 | 2003-11-18 | University Of Virginia Patent Foundation | Biological production of stable glutamine, poly-glutamine derivatives in transgenic organisms and their use for therapeutic purposes |
| US6762053B2 (en) * | 2000-06-09 | 2004-07-13 | Vitrolife, Inc. | Mammalian gamete and embryo culture media and culture media supplements |
| UY27505A1 (es) * | 2001-10-23 | 2003-06-30 | Boehringer Ingelheim Int | Tableta masticable que contiene lisina |
| US7070804B2 (en) * | 2001-10-23 | 2006-07-04 | Boehringer Ingelheim International Gmbh | Chewable tablet containing lysine |
| JP2012149096A (ja) * | 2001-12-18 | 2012-08-09 | Daicho Kikaku:Kk | 抗炎症剤 |
| WO2003066110A1 (en) * | 2002-02-01 | 2003-08-14 | Gambro, Inc. | Pathogen reduction solution for platelets containing an endogenous photosensitizer and a glycolysis inhibitor. |
| US20040029097A1 (en) * | 2002-04-16 | 2004-02-12 | Gambro, Inc. | Addition of glycolysis inhibitor to a pathogen reduction and storage solution |
| WO2005041689A2 (en) * | 2003-10-30 | 2005-05-12 | Quest International B.V. | Flavouring composition and method of flavouring foodstuffs or beverages |
| JP5177785B2 (ja) * | 2004-11-02 | 2013-04-10 | 味の素株式会社 | 周術期患者用薬剤 |
| DE102006018293A1 (de) * | 2006-04-20 | 2007-10-25 | Fresenius Kabi Deutschland Gmbh | Pädiatrische Aminosäurelösung zur parenteralen Ernäherung |
| CN115697084A (zh) * | 2020-04-01 | 2023-02-03 | 沃尔夫森医疗中心 | 溃疡性结肠炎膳食、配方、产品及其方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3206784A1 (de) * | 1982-02-25 | 1983-09-01 | Pfrimmer & Co Pharmazeutische Werke Erlangen Gmbh, 8520 Erlangen | Glutaminhaltige aminosaeure-zubereitungen |
| JPS61247354A (ja) * | 1984-11-19 | 1986-11-04 | ザ モンテフイオル ホスピタル アソシエ−シヨン オブ ウエスタ−ン ペンシルバニア | 栄養素組成物 |
| JPS62151156A (ja) * | 1985-08-07 | 1987-07-06 | Ajinomoto Co Inc | 栄養組成物 |
| WO1990011024A1 (fr) * | 1989-03-28 | 1990-10-04 | Kyowa Hakko Kogyo Co., Ltd. | Composition nutritive |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4024286A (en) * | 1976-05-17 | 1977-05-17 | Miles Laboratories, Inc. | Fortification of foodstuffs with C-terminal amino acid substituted methionine dipeptides |
| US4340592A (en) * | 1980-03-14 | 1982-07-20 | Adibi Siamak A | Nutrient compositions and method of administering the same |
| US5034377A (en) * | 1984-11-19 | 1991-07-23 | Montefiore Hospital Association Of Western Pennsylvania | Aqueous nutrient compositions comprising oligopeptides |
| US5102871A (en) * | 1989-04-24 | 1992-04-07 | Kyowa Hakko Kogyo Co., Ltd. | Nutrient composition |
| SE9003844L (sv) * | 1990-12-03 | 1992-06-04 | Kabi Pharmacia Ab | Naeringstillsats |
-
1993
- 1993-01-29 JP JP5014240A patent/JPH06227974A/ja not_active Withdrawn
-
1994
- 1994-01-26 US US08/295,842 patent/US5432160A/en not_active Expired - Fee Related
- 1994-01-26 WO PCT/JP1994/000101 patent/WO1994016688A1/ja not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3206784A1 (de) * | 1982-02-25 | 1983-09-01 | Pfrimmer & Co Pharmazeutische Werke Erlangen Gmbh, 8520 Erlangen | Glutaminhaltige aminosaeure-zubereitungen |
| JPS61247354A (ja) * | 1984-11-19 | 1986-11-04 | ザ モンテフイオル ホスピタル アソシエ−シヨン オブ ウエスタ−ン ペンシルバニア | 栄養素組成物 |
| JPS62151156A (ja) * | 1985-08-07 | 1987-07-06 | Ajinomoto Co Inc | 栄養組成物 |
| WO1990011024A1 (fr) * | 1989-03-28 | 1990-10-04 | Kyowa Hakko Kogyo Co., Ltd. | Composition nutritive |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06227974A (ja) | 1994-08-16 |
| US5432160A (en) | 1995-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0347890B1 (en) | Amino acid nutrient compositions | |
| CA2015186C (en) | Nutrient composition | |
| JPH031287B2 (ja) | ||
| WO1994016688A1 (en) | Nutritive composition | |
| JP4011638B2 (ja) | 経口経腸栄養組成物 | |
| JP2599593B2 (ja) | 腎不全用アミノ酸輸液 | |
| JPH01301619A (ja) | 癌用アミノ酸製剤 | |
| JP2683129B2 (ja) | 栄養組成物 | |
| JP3937423B2 (ja) | アミノ酸含有アルブミン製剤 | |
| JPWO1990011024A1 (ja) | 栄養組成物 | |
| JP2750467B2 (ja) | ペプチド混合物及び経腸栄養組成物 | |
| JPWO2000043035A1 (ja) | アミノ酸含有アルブミン製剤 | |
| JPS61502822A (ja) | 全非経口栄養及び経腸栄養組成物 | |
| JP3914585B2 (ja) | マクロファージ一酸化窒素産生亢進剤 | |
| JPS5916817A (ja) | アミノ酸輸液 | |
| JP3711400B2 (ja) | 輸液製剤 | |
| EP0634168A1 (en) | Nutritive composition | |
| JP2537406B2 (ja) | 癌用アミノ酸製剤 | |
| JPH07267855A (ja) | グルタミン産生剤 | |
| JP3456536B2 (ja) | 輸液製剤 | |
| JP4423682B2 (ja) | 輸液用グルタミン凍結乾燥物の調製法 | |
| JP3429327B2 (ja) | 癌用アミノ酸輸液剤 | |
| JP2744662B2 (ja) | 栄養組成物 | |
| JP3364932B2 (ja) | 輸液入り容器 | |
| JP3534535B2 (ja) | グルタミン含有栄養液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 08295842 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1994905207 Country of ref document: EP |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWP | Wipo information: published in national office |
Ref document number: 1994905207 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1994905207 Country of ref document: EP |

